Lecture 5: Management of patients with asthma Flashcards

1
Q

Define asthma

A

Asthma attacks all age groups but often starts in childhood. It is a disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. In an individual, they may occur from hour to hour and day to day. This condition is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they become easily irritated. In an attack, the lining of the passages swell causing the airways to narrow and reducing the flow of air in and out of the lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the aim of asthma therapy?

A

Achieve early control and maintain this by stepping up when necessary and stepping down treatment when control is good

  • No daytime symptoms
  • No night-time wakening due to asthma
  • No need for rescue medication (SABA)
  • No asthma attacks
  • No limitations on activity including exercise
  • Normal lung function (defined as PEFR >80% predicted or best)
  • Minimal side effects from medication
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What needs to be considered before initiating new therapy?

A
  • Check adherence with existing therapies
  • Check inhaler technique
  • Eliminate trigger factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What should you offer to people with newly diagnosed asthma or asthma that is uncontrolled?

A

Offer a SABA as reliver to adults (17 and over)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What should you give to adults (aged 17 and over) with asthma who have infrequent, short-lived wheeze and normal lung function

A

Treatment with SABA reliever therapy alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What should you give to adults with symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or asthma that is uncontrolled with a SABA alone.

A

Low dose of an ICS as the first-line maintenance therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is given for uncontrolled asthma in adults on a low dose of ICS as maintenance therapy?

A

Offer a leukotriene receptor antagonist (LTRA) in addition to the ICS and review the response to treatment in 4 to 8 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is given for uncontrolled asthma in adults (aged 17 and over) on a low dose of ICS and an LTRA as maintenance therapy

A

Offer a long-acting beta2 agonist (LABA) in combination with the ICS, and review LTRA treatment as follows

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is given to patients if asthma is uncontrolled in adults (aged 17 and over) on a low dose of ICS and a LABA, with or without an LTRA, as maintenance therapy?

A

ffer to change the person’s ICS and LABA maintenance therapy to a MART regimen with a low maintenance ICS dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is offered to 5-16 year olds with newly diagnosed asthma?

A

SABA as reliever therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is given to children and young people (aged 5 to 16) with asthma who have infrequent, short-lived wheeze and normal lung function?

A

Treatment with SABA reliever therapy alone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is given to 5-16 year olds with symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or asthma that is uncontrolled with a SABA alone?

A

paediatric low dose of an ICS as the first-line maintenance therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is given to 5-16 year olds if asthma is uncontrolled and on a paediatric low dose of ICS as maintenance therapy?

A

Consider an LTRA in addition to the ICS and review the response to treatment in 4 to 8 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the symptoms of poorly controlled asthma?

A
  • Wheeze
  • Cough - usually at night
  • Poor exercise capacity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What actions should be taken in patients with poorly controlled asthma?

A
  • Check inhaler technique
  • Check compliance with inhaled medicines
  • Establish any trigger factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe inhalation route

A

This route delivers the drug directly to the airways; the dose required is smaller than when given by mouth and side-effects are reduced.

17
Q

What do inhaler devices include?

A
  • pressurised metered-dose inhalers
  • breath-actuated inhalers
  • dry powder inhalers.
18
Q

What are spacer devices?

A

Remove the need to co-ordinate actuation with inhalation.

19
Q

When should a spacer be used?

A

Should always be used if the patient is on a high dose of inhaled corticosteroid.

20
Q

Why do brand and inhaler need to be specified when prescribing?

A

To help reduce confusion and ensure patients receive inhalers they have been given training for

21
Q

What does a nebuliser do?

A

Converts a solution of a drug into an aerosol for inhalation. It is used to deliver higher doses of drug to the airways than is usual with standard inhalers

22
Q

What lifestyle changes should be offered to patients with asthma?

A
  • Weight loss in overweight patients may lead to improve
  • Breathing exercise programmed can be offered to improve quality of life and reduce symptoms
  • Advise about the dangers of smoking
23
Q

What is intermittent reliever therapy?

A

Start an inhaled short-acting beta2 agonist (such as salbutamol or terbutaline sulfate),

24
Q

What is regular preventer maintenance therapy?

A

A low-dose of inhaled corticosteroid (ICS) should be started as maintenance therapy in patients who present with any one of the following features: using an inhaled short-acting beta2 agonist three times a week or more, symptomatic three times a week or more, or waking at night due to asthma symptoms at least once a week.

25
Q

Name the monoclonal antibodies?

A
  • Omalizumab
  • Mepolizumab
  • Benralizumab
  • Reslizumab
  • Dupilumab